Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses

By sjmartinez • November 16, 2022

Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser CB, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. JCI Insight. 2022 Nov 15:e163471. doi: 10.1172/jci.insight.163471. Epub ahead of print. PMID: 36378539.

Tags: Adaptive immunity, covid-19, Immunology, Infectious Diseases, Publications

Related Posts

PenA Alleles Associated With Gonococcal Ceftriaxone Resistance in Cambodia, China, and Vietnam

van der Veen S, Sun X, Ge H, Chau TM, Nhung PH, Vandelannoote K, Delvallez G, Cheng S, Laumen JGE, Adamson PC. PenA Alleles Associated[...]

Cefixime for the Treatment of Neisseria gonorrhoeae Infections in a Setting With Increased Antimicrobial Resistance: A Retrospective Study in Hanoi, Vietnam

Adamson PC, David HM, Pham LQ, Bui HTM, Le HHL, Pham QH, Le DH, Giang LM, Klausner JD. Cefixime for the Treatment of Neisseria gonorrhoeae[...]

cGAS-STING dependent type I IFN reduces Leptospira interrogans renal colonization in mice

Gupta S, Matsunaga J, Ratitong B, Manion A, Ismaeel S, Valadares DG, West AP, Kerur N, Stehlik C, Dorfleutner A, Dagvadorj J, Coburn J, Wolf[...]